The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how his team worked to reduce deleterious ASM interactions.
“What we learned was patients could get sleepy on clobazam and so by reducing that medication, we were able to keep many more patients on. When you look at the various ASMs, you have to look at the potential interactions that might occur with various medicines.”
Post hoc analysis from a phase 3 study presented at the American Epilepsy Society (AES) Annual Meeting, December 4–8, 2020, suggest that reducing doses of concomitant antiseizure medications (ASMs) led to fewer patients with focal seizures discontinuing cenobamate (Xcopri; SK Life Science).
The data, presented by William Rosenfeld, MD, neurologist, Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, showed that patients who continued on cenobamate had greater decreases in mean concomitant ASM use (first vs last dose) compared to those who discontinued treatment. Dose decreases were mostly due to adverse events, mainly during titration or early maintenance phases when cenobamate doses were escalated.
NeurologyLive spoke with Rosenfeld to learn more about cenobamate and its interactions with other concomitant medications. The SK Life Science product was approved in late 2019 for the treatment of partial-onset seizures.
For more coverage of AES 2020, click here.